Treatment with liposomal amphotericin B of a child affected with drug-resistant visceral leishmaniasis.
1993
R Giacchino, and
G Giambartolomei, and
L Tasso, and
A Timitilli, and
E Castagnola, and
M Brisigotti, and
C Micalizzi
Department of Infectious Diseases, G. Gaslini Children's Hospital, Genova, Italy.
UI
MeSH Term
Description
Entries
D007898
Leishmaniasis, Visceral
A chronic disease caused by LEISHMANIA DONOVANI and transmitted by the bite of several sandflies of the genera Phlebotomus and Lutzomyia. It is commonly characterized by fever, chills, vomiting, anemia, hepatosplenomegaly, leukopenia, hypergammaglobulinemia, emaciation, and an earth-gray color of the skin. The disease is classified into three main types according to geographic distribution: Indian, Mediterranean (or infantile), and African.
Black Fever,Kala-Azar,Fever, Black,Kala Azar,Visceral Leishmaniasis
D008297
Male
Males
D002675
Child, Preschool
A child between the ages of 2 and 5.
Children, Preschool,Preschool Child,Preschool Children
D004351
Drug Resistance
Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration.
Resistance, Drug
D006801
Humans
Members of the species Homo sapiens.
Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000666
Amphotericin B
Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela.
Amphocil,Amphotericin,Amphotericin B Cholesterol Dispersion,Amphotericin B Colloidal Dispersion,Fungizone
Related Publications
R Giacchino, and
G Giambartolomei, and
L Tasso, and
A Timitilli, and
E Castagnola, and
M Brisigotti, and
C Micalizzi